Assistant Professor, Department of Medical Biophysics, Western University
Corey Baron is an Assistant Professor of Medical Biophysics and a Robarts Scientist. His expertise includes high field diffusion MRI, MRI physics and image reconstruction, and his lab develops and applies ultra high field quantitative MRI to uncover new imaging biomarkers for and obtain a greater understanding of the brain and neurological conditions.
How can we efficiently measure multidimensional imaging biomarkers?
While the measurement of a whole plethora of tissue parameters seems like a great idea in principle, it is limited in practice by how long a patient can stay in your scanner. In order to make this practical in the clinic, we need to find ways to measure the information much more efficiently. One part of the solution is to work at ultra-high field, where there is more signal strength that can be used to accelerate the scans. Also, every single parameter map acquired in a session looks like a brain – the same brain, in fact. Accordingly, there is a lot of redundancy in the data that we can potentially exploit to reduce the amount of raw data we need to acquire to get the same information.
Can we use diffusion-based virtual microscopy of the brain to gain a better understanding of changes that occur during development or disease?
MRI is typically used to assess structures with length scales of millimeters or centimeters. Advanced forms of diffusion MRI give us an ability to assess microscopic characteristics of brain tissue, down to cellular length scales, which gives us an opportunity to learn more about disorders at a very fundamental level.
Can multidimensional imaging biomarkers detect neurodegenerative disorders, like Alzheimer’s disease or Parkinson’s disease, before symptoms occur?
Neurodegenerative disorders are associated with volume decreases in certain structures in the brain, but by the time this occurs symptoms like dementia are already present. However, it is likely that the brain is already subtly changing before symptoms begin. Multidimensional biomarkers may give more sensitivity to detect small changes in the brain sooner, which could allow earlier treatment before irreversible damage occurs.